Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants

Regina Heidenreich, Marcia Machein, Anke Nicolaus, Andreas Hilbig, Carola Wild, Matthias Clauss, Karl H. Plate, Georg Breier

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) and the high-affinity VEGF receptor Flk-1/KDR (VEGFR-2) are key regulators of tumor angiogenesis. Strategies to block VEGF/VEGFR-2 signaling were successfully used to inhibit experimental tumor growth and indicated that VEGFR-2 is the main signaling VEGF receptor in proliferating tumor endothelium. Here, we investigated the role of the VEGF receptor-1 (VEGFR-1/Flt-1) in the vascularization of 2 different experimental tumors in vivo. VEGFR-1 mutants were generated that lack the intracellular tyrosine kinase domain. Retrovirus-mediated gene transfer of the VEGFR-1 mutants led to a strong reduction of tumor growth and angiogenesis in xenografted Co glioma and in syngeneic BFS-1 fibrosarcoma. Histological analysis of the inhibited fibrosarcoma revealed reduced vascular density, decreased tumor cell proliferation as well as increased tumor cell apoptosis and the formation of necrosis. The retroviral gene transfer of the full length VEGFR-1 also caused a significant reduction of tumor growth in both models. The inhibitory effects of the VEGFR-1 mutants and the full length VEGFR-1 in BFS-1 fibrosarcoma were mediated through host tumor endothelial cells because the BFS-1 fibrosarcoma cells were not infected by the retrovirus. The formation of heterodimers between VEGFR-2 and full length or truncated VEGFR-1 was observed in vitro and might contribute to the growth inhibitory effect by modulating distinct signal transduction pathways. The results of our study underline the central role of the VEGF/VEGFR-1 signaling system in tumor angiogenesis and demonstrate that VEGFR-1 can serve as a target for anti-angiogenic gene therapy.

Original languageEnglish (US)
Pages (from-to)348-357
Number of pages10
JournalInternational Journal of Cancer
Volume111
Issue number3
DOIs
StatePublished - Sep 1 2004
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor-1
Growth
Vascular Endothelial Growth Factor Receptor-2
Genes
Neoplasms
Fibrosarcoma
Vascular Endothelial Growth Factor A
Retroviridae
Vascular Endothelial Growth Factor Receptor
Glioma
Genetic Therapy
Protein-Tyrosine Kinases
Endothelium
Blood Vessels
Signal Transduction
Necrosis
Endothelial Cells
Cell Proliferation

Keywords

  • Fibrosarcoma
  • Glioma
  • Tumor angiogenesis
  • VEGF receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Heidenreich, R., Machein, M., Nicolaus, A., Hilbig, A., Wild, C., Clauss, M., ... Breier, G. (2004). Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. International Journal of Cancer, 111(3), 348-357. https://doi.org/10.1002/ijc.20260

Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. / Heidenreich, Regina; Machein, Marcia; Nicolaus, Anke; Hilbig, Andreas; Wild, Carola; Clauss, Matthias; Plate, Karl H.; Breier, Georg.

In: International Journal of Cancer, Vol. 111, No. 3, 01.09.2004, p. 348-357.

Research output: Contribution to journalArticle

Heidenreich, R, Machein, M, Nicolaus, A, Hilbig, A, Wild, C, Clauss, M, Plate, KH & Breier, G 2004, 'Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants', International Journal of Cancer, vol. 111, no. 3, pp. 348-357. https://doi.org/10.1002/ijc.20260
Heidenreich, Regina ; Machein, Marcia ; Nicolaus, Anke ; Hilbig, Andreas ; Wild, Carola ; Clauss, Matthias ; Plate, Karl H. ; Breier, Georg. / Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. In: International Journal of Cancer. 2004 ; Vol. 111, No. 3. pp. 348-357.
@article{cf4d21978e34443085514162fd63b8de,
title = "Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants",
abstract = "Vascular endothelial growth factor (VEGF) and the high-affinity VEGF receptor Flk-1/KDR (VEGFR-2) are key regulators of tumor angiogenesis. Strategies to block VEGF/VEGFR-2 signaling were successfully used to inhibit experimental tumor growth and indicated that VEGFR-2 is the main signaling VEGF receptor in proliferating tumor endothelium. Here, we investigated the role of the VEGF receptor-1 (VEGFR-1/Flt-1) in the vascularization of 2 different experimental tumors in vivo. VEGFR-1 mutants were generated that lack the intracellular tyrosine kinase domain. Retrovirus-mediated gene transfer of the VEGFR-1 mutants led to a strong reduction of tumor growth and angiogenesis in xenografted Co glioma and in syngeneic BFS-1 fibrosarcoma. Histological analysis of the inhibited fibrosarcoma revealed reduced vascular density, decreased tumor cell proliferation as well as increased tumor cell apoptosis and the formation of necrosis. The retroviral gene transfer of the full length VEGFR-1 also caused a significant reduction of tumor growth in both models. The inhibitory effects of the VEGFR-1 mutants and the full length VEGFR-1 in BFS-1 fibrosarcoma were mediated through host tumor endothelial cells because the BFS-1 fibrosarcoma cells were not infected by the retrovirus. The formation of heterodimers between VEGFR-2 and full length or truncated VEGFR-1 was observed in vitro and might contribute to the growth inhibitory effect by modulating distinct signal transduction pathways. The results of our study underline the central role of the VEGF/VEGFR-1 signaling system in tumor angiogenesis and demonstrate that VEGFR-1 can serve as a target for anti-angiogenic gene therapy.",
keywords = "Fibrosarcoma, Glioma, Tumor angiogenesis, VEGF receptor",
author = "Regina Heidenreich and Marcia Machein and Anke Nicolaus and Andreas Hilbig and Carola Wild and Matthias Clauss and Plate, {Karl H.} and Georg Breier",
year = "2004",
month = "9",
day = "1",
doi = "10.1002/ijc.20260",
language = "English (US)",
volume = "111",
pages = "348--357",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants

AU - Heidenreich, Regina

AU - Machein, Marcia

AU - Nicolaus, Anke

AU - Hilbig, Andreas

AU - Wild, Carola

AU - Clauss, Matthias

AU - Plate, Karl H.

AU - Breier, Georg

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Vascular endothelial growth factor (VEGF) and the high-affinity VEGF receptor Flk-1/KDR (VEGFR-2) are key regulators of tumor angiogenesis. Strategies to block VEGF/VEGFR-2 signaling were successfully used to inhibit experimental tumor growth and indicated that VEGFR-2 is the main signaling VEGF receptor in proliferating tumor endothelium. Here, we investigated the role of the VEGF receptor-1 (VEGFR-1/Flt-1) in the vascularization of 2 different experimental tumors in vivo. VEGFR-1 mutants were generated that lack the intracellular tyrosine kinase domain. Retrovirus-mediated gene transfer of the VEGFR-1 mutants led to a strong reduction of tumor growth and angiogenesis in xenografted Co glioma and in syngeneic BFS-1 fibrosarcoma. Histological analysis of the inhibited fibrosarcoma revealed reduced vascular density, decreased tumor cell proliferation as well as increased tumor cell apoptosis and the formation of necrosis. The retroviral gene transfer of the full length VEGFR-1 also caused a significant reduction of tumor growth in both models. The inhibitory effects of the VEGFR-1 mutants and the full length VEGFR-1 in BFS-1 fibrosarcoma were mediated through host tumor endothelial cells because the BFS-1 fibrosarcoma cells were not infected by the retrovirus. The formation of heterodimers between VEGFR-2 and full length or truncated VEGFR-1 was observed in vitro and might contribute to the growth inhibitory effect by modulating distinct signal transduction pathways. The results of our study underline the central role of the VEGF/VEGFR-1 signaling system in tumor angiogenesis and demonstrate that VEGFR-1 can serve as a target for anti-angiogenic gene therapy.

AB - Vascular endothelial growth factor (VEGF) and the high-affinity VEGF receptor Flk-1/KDR (VEGFR-2) are key regulators of tumor angiogenesis. Strategies to block VEGF/VEGFR-2 signaling were successfully used to inhibit experimental tumor growth and indicated that VEGFR-2 is the main signaling VEGF receptor in proliferating tumor endothelium. Here, we investigated the role of the VEGF receptor-1 (VEGFR-1/Flt-1) in the vascularization of 2 different experimental tumors in vivo. VEGFR-1 mutants were generated that lack the intracellular tyrosine kinase domain. Retrovirus-mediated gene transfer of the VEGFR-1 mutants led to a strong reduction of tumor growth and angiogenesis in xenografted Co glioma and in syngeneic BFS-1 fibrosarcoma. Histological analysis of the inhibited fibrosarcoma revealed reduced vascular density, decreased tumor cell proliferation as well as increased tumor cell apoptosis and the formation of necrosis. The retroviral gene transfer of the full length VEGFR-1 also caused a significant reduction of tumor growth in both models. The inhibitory effects of the VEGFR-1 mutants and the full length VEGFR-1 in BFS-1 fibrosarcoma were mediated through host tumor endothelial cells because the BFS-1 fibrosarcoma cells were not infected by the retrovirus. The formation of heterodimers between VEGFR-2 and full length or truncated VEGFR-1 was observed in vitro and might contribute to the growth inhibitory effect by modulating distinct signal transduction pathways. The results of our study underline the central role of the VEGF/VEGFR-1 signaling system in tumor angiogenesis and demonstrate that VEGFR-1 can serve as a target for anti-angiogenic gene therapy.

KW - Fibrosarcoma

KW - Glioma

KW - Tumor angiogenesis

KW - VEGF receptor

UR - http://www.scopus.com/inward/record.url?scp=3242892737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242892737&partnerID=8YFLogxK

U2 - 10.1002/ijc.20260

DO - 10.1002/ijc.20260

M3 - Article

C2 - 15221961

AN - SCOPUS:3242892737

VL - 111

SP - 348

EP - 357

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -